Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 49

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 49
---
us and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Accordingly, our management will have flexibility in applying the net proceeds from this offering. An investor will not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds.

<div align='center'>25

DIVIDEND POLICY</div>

We have not declared any cash dividends since
inception and we do not anticipate paying any dividends in the foreseeable future. Instead, we anticipate that all of our earnings will
be used to provide working capital, to support our operations, and to finance the growth and development of our business. The payment
of dividends is within the discretion of the Board and will depend on our earnings, capital requirements, financial condition, prospects,
operating results, cash needs, growth plans, applicable Delaware law, which provides that dividends are only payable out of surplus or
current net profits, and other factors our board might deem relevant. There are no restrictions that currently limit our ability to pay
dividends on our common stock other than those generally imposed by applicable state law.

<div align='center'>CAPITALIZATION</div>

The following table sets forth our consolidated
cash and capitalization as of March 31, 2025:

| ● | On                   
 an actual basis; and |

| ● | On an as adjusted basis giving effect to the sale of up to                shares                                                       
 of common stock, or, in lieu thereof, Pre-Funded Warrants to purchase up to                 shares                                     
 of common stock, and accompanying Series A-1 Warrants to purchase up to                  shares                                        
 of common stock and Series A-2 Warrants to purchase up to                shares                                                        
 of common stock by us in this public offering at an assumed public offering price of $                                                 
 per share (the last reported sale price of our common stock on The Nasdaq Capital Market on                   ,                        
 2025), after deducting estimated placement agent fees and estimated offering expenses payable by us, and assuming exercise in full of  
 any Pre-Funded Warrants offered in this offering, no exercise of the Series A-1 Warrants and Series A-2 Warrants being offered in this 
 offering and no value being attributed to the Warrants.                                                                                |

You should read the following table in conjunction with the section
titled “Use of Proceeds” in this prospectus and “Management’s Discussion and Analysis of Financial Condition and Results of Operations